Immunotech Laboratories Stock

Immunotech Laboratories Tangible Book Value per Share

The Tangible Book Value per Share of Immunotech Laboratories (IMMB) as of Aug 16, 2026 is 161.04 USD.

Tangible Book Value per Share

161.04USD

Last updated:

Tangible Book Value per Share of Immunotech Laboratories is 2026 161.04 USD. Tangible Book Value per Share of Immunotech Laboratories was 2025 - USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Immunotech Laboratories Stock analysis

What does Immunotech Laboratories do? Immunotech Laboratories Inc is a biotechnology company specializing in the development and marketing of immunotherapies for the treatment of various diseases. The company was founded in 2005 in California, USA. Immunotech Laboratories focuses on the development of immunotherapies for diseases such as HIV/AIDS, Hepatitis C, cancer, and autoimmune diseases. The business model of Immunotech Laboratories is based on the development of innovative immunotherapies using natural compounds. The company collaborates closely with leading scientists and experts in the field of immunology. The developed therapies undergo various clinical trials and are commercially distributed upon successful approval. Immunotech Laboratories specializes in different areas in order to offer a wide range of therapies to its customers. For example, the company develops immunotherapies for the treatment of HIV/AIDS. Immunotech Laboratories combines different compounds to reduce viral load in the body and aid the immune system in fighting the infection. Another important area for Immunotech Laboratories is the development of immunotherapies for cancer treatment. The company utilizes innovative approaches that enable the body's natural defenses to recognize and combat cancer cells. Combination of different compounds is also employed to enhance effectiveness. In addition to these areas, Immunotech Laboratories also offers immunotherapies for the treatment of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company employs innovative approaches that enable the immune system to recognize and fight pathogens causing these diseases. Immunotech Laboratories offers a range of products developed based on immunotherapies. These include different combinations of compounds for the treatment of HIV/AIDS and Hepatitis C, as well as immunotherapies for cancer and autoimmune diseases. These products are available in the form of injections, capsules, or tablets and can be prescribed by physicians. Overall, Immunotech Laboratories is an innovative biotechnology company specializing in the development and marketing of immunotherapies. The company collaborates with leading experts in immunology and develops innovative approaches for the treatment of various diseases. The offered products are known for their high effectiveness and tolerability, helping patients worldwide improve their health. Immunotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunotech Laboratories stock

Tangible Book Value per Share of Immunotech Laboratories is 161.04 USD in 2026.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Immunotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

Balance Sheet — Immunotech Laboratories

All Key Metrics — Immunotech Laboratories